Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 2, 2006, Pages 93-98

  Duarte Mendes, G ^a,b   Dantas Sanfelice, A T ^a   do Carmo Borges, N C ^a   Cavedal, L E ^a   Sverdloff, C ^b   Prado Galuppo, M ^b   Modolo J H ^b   De Nucci, G ^a,b,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cartesius Development of Clinical Research   (Brazil)

^c NONE   (Brazil)

Author keywords

Bioavailability; LC MS MS; Pharmacokinetics; Tandem mass spectrometry

Indexed keywords

EDETIC ACID; ENALAPRIL; ENALAPRILAT; RAMIPRIL; RAMIPRILAT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; FOOD AND DRUG ADMINISTRATION; GEOMETRY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; OPEN STUDY; POSITIVE ION ELECTROSPRAY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; VOLUNTEER;

EID: 32544461442     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp44093     Document Type: Article

References (15)

1. Al-Majed AA, Belal F, Abadi A, Al-Obaid AM 2000 The voltametric study and determination of ramipril in dosage forms and biological fluids. Farmaco 55: 233-238
2. Becker RH, Scholkens BA, Metzger M, Schulze KJ 1984 Pharmacological properties of the new orally active angiotensin-converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498). Arzneimittelforschung 34: 1411-1416
3. Belal F, Al-Zaagi IA, Gadkariem EA, Abounassif MA 2001 A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms. J Pharm Biomed Anal 24: 335-342
4. Bonazzi D, Gotti R, Andrisano V, Cavrini V 1997 Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC). J Pharm Biomed Anal 16: 431-438
5. Campbell DJ, Kladis A, Duncan AM 1993 Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 2: 513-522
6. Food and Drug Administration 1993 In vivo bioequivalence guidances. Pharmacopeia 19: 6501-6508
7. Food and Drug Administration 1998 Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions-FDA. Proposed rule. Fed Regist 63: 64222-64228
8. Hogan BL, Williams M, Idiculla A, Veysoglu T, Parente E 2000 Development and validation of a liquid chromatographic method for the determination of the related substances of ramipril in Altace capsules. J Pharm Biomed Anal 23: 637-651
9. Lee ID, Hunt TL, Bradley CR, Copp C, Griffiths L, Brobst-Kromer J 1996 Effects on the pharmacokinetics and pharmacodynamics in the elderly of coadministering ramipril with water, apple juice, and applesauce. J Pharm Res 13: 639-642
10. Maurer HH, Kraemer T, Arlt JW 1998 Screening for the detection of angiotensin-converting enzyme inhibitors, their metabolites and ATH receptor antagonists. Ther Drug Monit 20: 706-713
11. Nussberger J, Brunner DB, Waeber B, Brunner HR 1985 True versus immunoreactive angiotensin II in human plasma. Hypertension 7: 1-7
12. Unger T, Moursi M, Ganten D, Hermann K, Lang RE 1986 Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498). J Cardiovasc Pharmacol 8: 276-285
13. Van Griensven JM, Schoemaker RC, Cohen AF, Luus HG, Seibert-Grafe M, Rothig HJ 1995 Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol 47: 513-518
14. Verho M, Luck C, Stelter WJ, Rangoonwala B, Bender N 1995 Pharmacokinetics metabolism and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin 13: 264-273
15. Zhu Z, Vachareau A, Neirinck L 2002 Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 779: 297-306